Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Doravirine/Islatravir in Heavily Treatment-Experienced HIV-1-Infected Participants
jRCT2080225147Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of islatravir, doravirine and doravirine + islatravir in Human immunodeficiency virus infection type 1 (5 arms), sponsored by Merck & Co. Primary endpoints: Short-term antiretroviral activity of DOR/ISL versus placebo, Short-term antiretroviral activity of islatravir monotherapy versus placebo and 2 more. Started Mar 2020; status: completed.
02
Drugs
islatravirdoravirinedoravirine + islatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2080225147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225147.